Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

H Amiri, A de Sitter, K Bendfeldt, M Battaglini, CAM Gandini Wheeler-Kingshott, M Calabrese, JJG Geurts, MA Rocca, J Sastre-Garriga, C Enzinger, N de Stefano, M Filippi, Á Rovira, F Barkhof, H Vrenken, MAGNIMS Study Group

Research output: Contribution to journalArticle

Abstract

Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS. © 2018 The Authors
Original languageEnglish
Pages (from-to)466-475
Number of pages10
JournalNeuroImage: Clinical
Volume19
DOIs
Publication statusPublished - 2018

Fingerprint

Multiple Sclerosis
Atrophy
Brain
Clinical Trials
Gray Matter
Therapeutics

Cite this

Amiri, H., de Sitter, A., Bendfeldt, K., Battaglini, M., Gandini Wheeler-Kingshott, CAM., Calabrese, M., ... Group, MAGNIMS. S. (2018). Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. NeuroImage: Clinical, 19, 466-475. https://doi.org/10.1016/j.nicl.2018.04.023

Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. / Amiri, H; de Sitter, A; Bendfeldt, K; Battaglini, M; Gandini Wheeler-Kingshott, CAM; Calabrese, M; Geurts, JJG; Rocca, MA; Sastre-Garriga, J; Enzinger, C; de Stefano, N; Filippi, M; Rovira, Á; Barkhof, F; Vrenken, H; Group, MAGNIMS Study.

In: NeuroImage: Clinical, Vol. 19, 2018, p. 466-475.

Research output: Contribution to journalArticle

Amiri, H, de Sitter, A, Bendfeldt, K, Battaglini, M, Gandini Wheeler-Kingshott, CAM, Calabrese, M, Geurts, JJG, Rocca, MA, Sastre-Garriga, J, Enzinger, C, de Stefano, N, Filippi, M, Rovira, Á, Barkhof, F, Vrenken, H & Group, MAGNIMSS 2018, 'Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI', NeuroImage: Clinical, vol. 19, pp. 466-475. https://doi.org/10.1016/j.nicl.2018.04.023
Amiri, H ; de Sitter, A ; Bendfeldt, K ; Battaglini, M ; Gandini Wheeler-Kingshott, CAM ; Calabrese, M ; Geurts, JJG ; Rocca, MA ; Sastre-Garriga, J ; Enzinger, C ; de Stefano, N ; Filippi, M ; Rovira, Á ; Barkhof, F ; Vrenken, H ; Group, MAGNIMS Study. / Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. In: NeuroImage: Clinical. 2018 ; Vol. 19. pp. 466-475.
@article{8b721869e10d46a9bca066291bfeddb9,
title = "Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI",
abstract = "Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS. {\circledC} 2018 The Authors",
author = "H Amiri and {de Sitter}, A and K Bendfeldt and M Battaglini and {Gandini Wheeler-Kingshott}, CAM and M Calabrese and JJG Geurts and MA Rocca and J Sastre-Garriga and C Enzinger and {de Stefano}, N and M Filippi and {\'A} Rovira and F Barkhof and H Vrenken and Group, {MAGNIMS Study}",
year = "2018",
doi = "10.1016/j.nicl.2018.04.023",
language = "English",
volume = "19",
pages = "466--475",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
publisher = "ELSEVIER SCI LTD",

}

TY - JOUR

T1 - Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

AU - Amiri, H

AU - de Sitter, A

AU - Bendfeldt, K

AU - Battaglini, M

AU - Gandini Wheeler-Kingshott, CAM

AU - Calabrese, M

AU - Geurts, JJG

AU - Rocca, MA

AU - Sastre-Garriga, J

AU - Enzinger, C

AU - de Stefano, N

AU - Filippi, M

AU - Rovira, Á

AU - Barkhof, F

AU - Vrenken, H

AU - Group, MAGNIMS Study

PY - 2018

Y1 - 2018

N2 - Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS. © 2018 The Authors

AB - Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS. © 2018 The Authors

U2 - 10.1016/j.nicl.2018.04.023

DO - 10.1016/j.nicl.2018.04.023

M3 - Article

VL - 19

SP - 466

EP - 475

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

ER -